RT Journal Article
T1 Pseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors.
A1 Royo-Cebrecos, Cristina
A1 Laporte-Amargós, Julia
A1 Peña, Marta
A1 Ruiz-Camps, Isabel
A1 Puerta-Alcalde, Pedro
A1 Abdala, Edson
A1 Oltolini, Chiara
A1 Akova, Murat
A1 Montejo, Miguel
A1 Mikulska, Malgorzata
A1 Martín-Dávila, Pilar
A1 Herrera, Fabian
A1 Gasch, Oriol
A1 Drgona, Lubos
A1 Morales, Hugo Manuel Paz
A1 Brunel, Anne-Sophie
A1 García, Estefanía
A1 Isler, Burcu
A1 Kern, Winfried V
A1 Palacios-Baena, Zaira R
A1 de la Calle, Guillermo Maestro
A1 Montero, Maria Milagro
A1 Kanj, Souha S
A1 Sipahi, Oguz R
A1 Calik, Sebnem
A1 Márquez-Gómez, Ignacio
A1 Marin, Jorge I
A1 Gomes, Marisa Z R
A1 Hemmatti, Philipp
A1 Araos, Rafael
A1 Peghin, Maddalena
A1 Del Pozo, José Luis
A1 Yáñez, Lucrecia
A1 Tilley, Robert
A1 Manzur, Adriana
A1 Novo, Andrés
A1 Carratalà, Jordi
A1 Gudiol, Carlota
A1 IRONIC study group, 
K1 Pseudomonas aeruginosa
K1 bacteremia
K1 bloodstream infection
K1 cancer
K1 hematologic malignancy
K1 solid tumor
AB Objectives: To assess the clinical features and outcomes of Pseudomonas aeruginosa bloodstream infection (PA BSI) in neutropenic patients with hematological malignancies (HM) and with solid tumors (ST), and identify the risk factors for 30-day mortality. Methods: We performed a large multicenter, retrospective cohort study including onco-hematological neutropenic patients with PA BSI conducted across 34 centers in 12 countries (January 2006−May 2018). Episodes occurring in hematologic patients were compared to those developing in patients with ST. Risk factors associated with 30-day mortality were investigated in both groups. Results: Of 1217 episodes of PA BSI, 917 occurred in patients with HM and 300 in patients with ST. Hematological patients had more commonly profound neutropenia (0.1 × 109 cells/mm) (67% vs. 44.6%; p
SN 2076-0817
YR 2022
FD 2022-09-30
LK http://hdl.handle.net/10668/21531
UL http://hdl.handle.net/10668/21531
LA en
DS RISalud
RD Apr 11, 2025